ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2187

Anti-Phosholipid Antibodies and Female Infertility: A Systematic Revision of Literature

Cecilia B. Chighizola1, Guilherme Ramires de Jesus2 and W. David Branch3, 1Department of Clinical Sciences and Community Health, University of Milan, Istituto Auxologico Italiano, Cusano Milanino, Italy, 2Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 3Obstetrics and Gynecology, University of Utah and Intermountain Healthcare, Salt Lake City, UT

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Antiphospholipid antibodies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Antiphospholipid Syndrome: Clinical

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Infertility is a
common condition, affecting 8-12% of couples in childbearing age. Even
though the association of aPL with infertility is highly debated, infertile
women are commonly screened for anti-phospholipid antibodies (aPL). Therefore,
the aim of this work was to accurately review available evidence.

 

Methods:

A systematic
PubMed search was conducted to retrieve papers addressing the: i) association
between aPL positivity and infertility, ii) positivity rate of criteria and non
criteria aPL in infertile women and iii) association between aPL positivity and
ART outcome. aPL positivity rates in infertile women and controls were calculated
as median (25-75 percentiles); differences in aPL positivity rate between
patients and controls were evaluated by Wilcoxon matched-pair test. The
strength of association between aPL positivity and both infertility and outcome
of assisted reproduction technologies (ART) were expressed as the rate of
studies confirming a positive association.

 

Results:

A total of 39
papers were considered in this critical analysis.
There was a wide
heterogeneity in the selection of study and control populations; only 10% of
the studies presented a prospective design. aPL cut-offs conforming to
international guidelines were used in less than 25% of studies; aPL positivity
was confirmed in 11% of studies. Approximately half of the considered studies
assessed non criteria aPL tests. i) According
to our best estimates, the overall positivity rate of criteria aPL tests is 6%
(2-8.9) among infertile women and 1% (0-2.15) among controls. Non criteria aPL
tests were estimated to be positive in 3% (1.5-9) of study women and in 2%
(1-7) of controls. Table 1
reports the calculated frequencies of each of the considered tests in
patients and controls. A significant difference in the positivity
rate of patients versus controls emerged for anti-cardiolipin antibodies (aCL)
only (p<0.00001, 95% CI 3.35-8.50). ii)
The association rates between each aPL test and
infertility are detailed in Table 2. iii) Only 5 of the relevant 18 studies (27.7%) reported a
detrimental effect of aPL on ART outcome. Of these studies, 4 assayed only
criteria aPL tests and one aCL plus non-criteria aPL tests.

 

Conclusion:

According to our
literature revision, aPL are more frequently detected among infertile women than
controls; conversely, the association between aPL and ART outcome is not
supported by most studies. Data inconsistencies might be ascribed to the lack
of a true association or to literature limitations; well-designed studies are
warranted to produce strong evidence-based recommendations.

Table 1

aPL test

Number of studies

Number of patients/controls

Positivity rate                      (patients)

Positivity rate (controls)

Lupus anticoagulant

9

90 (56-137)/

100 (80-201)

0%

(0-2.5)

0%                            (0-0)

Anti-cardiolipin Abs

20

65 (47-131)/         

67 (34-194)

7%

(3.7-13.3)

1.6%                            (0-3)

Anti-b2 glycoprotein I Abs

1

105/106

7.6%

2.8%

Anti- phosphatidic acid Abs

7

43(42-96)/    

45 (42-124)

6%

(1.5-13.2)

5%              

(2-5.7)

Anti-phosphatidylcoline Abs

1

1991/205

4%

(2-5.8)

1%                          (0.8-1.4)

Anti- phosphatydilethanolamine Abs

7

96 (42.5-1048)/    

106 (43.5-164.5)

4.2%

(2-9)

2.5%                      (1.8-7.1)

Anti- phosphatidylglycerol Abs

5

43 (42-96)/        

45 (42-124)

3%

(2-7.5)

2%                            (0.9-4.5)

Anti-phosphatidylinositol Abs

6

69.5 (42-103)/             

75.5 (43-119.5)

3.8%

(1-5.5)

1%                            (0-5.7)

Anti- phosphatydilserine Abs

2

1013 (524-1502)/       

164 (144-184)

2%

(0.8-2)

2.8%                     (0.5-6.8)

Anti-prothrombin Abs

1

69/120

31.9%

8.3%

           

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Table 2

aPL test

Number of studies

Rate of association

Lupus anticoagulant

13

45%

Anti-cardiolipin Abs

29

31%

Anti-b2 glycoprotein I Abs

4

75%

Anti- phosphatidic acid Abs

9

44.4%

Anti-phosphatidylcoline Abs

6

83.3%

Anti- phosphatydilethanolamine Abs

12

53.3%

Anti- phosphatidylglycerol Abs

10

50%

Anti-phosphatidylinositol Abs

11

63.6%

Anti- phosphatydilserine Abs

7

/

Anti-prothrombin Abs

1

100%

 

 


Disclosure: C. B. Chighizola, None; G. Ramires de Jesus, None; W. D. Branch, None.

To cite this abstract in AMA style:

Chighizola CB, Ramires de Jesus G, Branch WD. Anti-Phosholipid Antibodies and Female Infertility: A Systematic Revision of Literature [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/anti-phosholipid-antibodies-and-female-infertility-a-systematic-revision-of-literature/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-phosholipid-antibodies-and-female-infertility-a-systematic-revision-of-literature/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology